Phases, active trials: Phase 1: 18, Phase 2: 18, Phase 3: 23, Other: 3
Incyte has built a focused clinical portfolio around kinase inhibition, JAK, FGFR, and IDH, with growing programs in checkpoint inhibition and CSF1R-targeted therapy. Jakafi (ruxolitinib), the first JAK1/2 inhibitor approved, remains central across myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease. Opzelura (ruxolitinib cream) extends the JAK franchise into dermatology, approved for atopic dermatitis and vitiligo, with ongoing trials in additional inflammatory skin conditions. Pemazyre (pemigatinib) pioneered FGFR inhibition in cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR1 rearrangements. Zynyz (retifanlimab), their PD-1 inhibitor, is approved in Merkel cell carcinoma and anal canal carcinoma, with expansion trials ongoing. Niktimvo (axatilimab), targeting CSF1R in chronic GvHD, represents a new mechanism in allogeneic transplant complications.
- Hematology (myelofibrosis, PV, GvHD)
- Oncology (FGFR, PD-1, IDH)
- Dermatology (atopic dermatitis, vitiligo)
- Bone marrow failure / transplant complications
- Solid tumors (cholangiocarcinoma, anal carcinoma)
- Jakafi (ruxolitinib): JAK1/2, myelofibrosis/PV/GvHD
- Opzelura (ruxolitinib cream): JAK1/2, atopic dermatitis/vitiligo
- Pemazyre (pemigatinib): FGFR1/2/3, cholangiocarcinoma/FGFR1 neoplasms
- Zynyz (retifanlimab): PD-1, Merkel cell/anal carcinoma
- Niktimvo (axatilimab): CSF1R, chronic GvHD
- INCB57643: BET bromodomain, AML/solid tumors
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or… NCT05836324 | Primary completion moved at least 2 years 3 months later | Recruiting |
8 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in… NCT06516952 | Oct 19, 2026 · Estimated | Phase 3 |
5 more on the Completions page. See the calendar →
Monitor the Incyte pipeline daily
Get a daily digest when Incyte registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Solid Tumors | 7 |
| Chronic Graft-versus-host-disease | 6 |
| Myeloproliferative Neoplasms | 5 |
| NonSegmental Vitiligo | 4 |
| Atopic Dermatitis | 3 |
| Hidradenitis Suppurativa | 3 |
| Hidradenitis Suppurativa (HS) | 3 |
| Ovarian Cancer | 3 |
Incyte's JAK inhibitor expansion, particularly Jakafi combinations in myelofibrosis (with BCL-2, BET inhibitors) and Opzelura label expansions in dermatology, generates consistent new trial registrations. Their FGFR inhibitor portfolio (pemigatinib, futibatinib partnership) is closely tracked in cholangiocarcinoma and urothelial cancer by oncology BD teams.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Incyte's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Incyte may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Incyte pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in… NCT07214779 | Recruiting | Trial sites expanded: 192 → 197 locations | 2026-10-10 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for… NCT06585774 | Recruiting | Trial sites expanded: 128 → 131 locations | 2026-10-10 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy… NCT07284849 | Recruiting | Trial sites expanded: 280 → 293 locations | 2026-10-10 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants… NCT07623200 | Recruiting | Trial sites expanded: 175 → 178 locations | 2026-10-09 |
| Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease NCT05919511 | Recruiting | Trial sites expanded: 32 → 37 locations | 2026-10-07 |
Each trial page shows every change DataLookout has recorded for that trial.